2020
DOI: 10.1111/1468-0009.12470
|View full text |Cite
|
Sign up to set email alerts
|

Situating the Continuum of Overdose Risk in the Social Determinants of Health: A New Conceptual Framework

Abstract: This article reconceptualizes our understanding of the opioid epidemic and proposes six strategies that address the epidemic's social roots. In order to successfully reduce drug‐related mortality over the long term, policymakers and public health leaders should develop partnerships with people who use drugs, incorporate harm reduction interventions, and reverse decades of drug criminalization policies. Context Drug overdose is the leading cause of injury‐related death in the United States. Synthetic opioids, … Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1

Citation Types

2
88
0

Year Published

2021
2021
2024
2024

Publication Types

Select...
7
1

Relationship

1
7

Authors

Journals

citations
Cited by 110 publications
(99 citation statements)
references
References 186 publications
2
88
0
Order By: Relevance
“…It should be noted that the reformulation is not entirely "abuse-proof," since it cannot eradicate oral misuse (i.e., taking more pills or higher doses than prescribed), and some users have even found ways to counteract the abuse-deterrent properties of the new version. 8 The FDA recently announced its intent to encourage the development of more opioid formulations with abuse-deterrent properties. 9 To date, the FDA has approved abuse-deterrent versions for several brand-name extended-release opioids (e.g., Targiniq, Embeda, Hysingla, MorphaBond, Xtampza, and Troxyca), though OxyContin remains the most important given its large market size.…”
Section: B the Oxycontin Reformulationmentioning
confidence: 99%
See 1 more Smart Citation
“…It should be noted that the reformulation is not entirely "abuse-proof," since it cannot eradicate oral misuse (i.e., taking more pills or higher doses than prescribed), and some users have even found ways to counteract the abuse-deterrent properties of the new version. 8 The FDA recently announced its intent to encourage the development of more opioid formulations with abuse-deterrent properties. 9 To date, the FDA has approved abuse-deterrent versions for several brand-name extended-release opioids (e.g., Targiniq, Embeda, Hysingla, MorphaBond, Xtampza, and Troxyca), though OxyContin remains the most important given its large market size.…”
Section: B the Oxycontin Reformulationmentioning
confidence: 99%
“…OxyContin was the first drug targeted for monitoring by the DEA by its brand name, specifically (GAO 2003) 7. This reformulated version received an official "abuse-deterrent" designation from the FDA in April 2013 8. Highly sophisticated methods were shared on websites for how to counteract the abuse-deterrent properties of the drug involving baking, freezing, or soaking the pill in solvents(Goodnough and Zezima 2011, Becker andFiellin 2017).…”
mentioning
confidence: 99%
“…Park et al ( 2020 ) outlines community as an underutilized area in which the crisis can be solved. The community sector encompasses the conditions in which people live, commute, and work.…”
Section: Sectors Of the Opioid Crisismentioning
confidence: 99%
“…Scholars and practitioners recognize the need for community-based approaches to address the opioid crisis. These could include drug checking programs and appointing PWUD (persons who use drugs) to leadership positions for designing anti-opioid strategy and policy may help (Park et al 2020 ). Leston et al ( 2019 ) suggest implementing prevention and help services into school curriculum.…”
Section: Sectors Of the Opioid Crisismentioning
confidence: 99%
“…A strong evidence base suggests that social and structural factors (e.g., peer, familial, school, neighborhood, health and social service system characteristics, jurisdiction and state characteristics) are critical to preventing and responding to the opioid epidemic among adults (Dasgupta et al, 2017 ; Park et al, 2020 ), but the relevance of these factors to adolescent opioid use has been understudied. Additionally, among Black and Latinx adolescents in particular, this topic has gone largely unexplored; (Ford & Rigg, 2015 ) and this is an important knowledge gap to address given that this population has a high likelihood of experiencing adverse health and social outcomes associated with use.…”
Section: Introductionmentioning
confidence: 99%